Chest Pain Labs and Next Steps: What Tests to Expect and When to Act

The core answer

Chest pain evaluation is a layered process, not a single test. An ECG and an initial high-sensitivity troponin are drawn immediately to look for an active heart attack; if both are reassuring, a second troponin a short interval later and a structured risk score such as HEART determine whether a person can be safely discharged the same day or needs observation, additional testing, or admission. This approach, formalized in the 2021 AHA/ACC multisociety chest pain guideline, is designed to catch time-sensitive conditions like myocardial infarction, pulmonary embolism, and aortic dissection quickly while avoiding unnecessary admissions for the many people whose chest pain turns out to be non-cardiac.

Disambiguating the terms you will hear

A few terms get used loosely and are worth separating early:

• hs-cTn (high-sensitivity cardiac troponin) is a blood test, not an imaging study. It measures a protein released when heart muscle cells are injured, from any cause, not only a heart attack.
• ECG (electrocardiogram) is a real-time electrical tracing of the heart, read in minutes, distinct from imaging tests like echocardiography or CT angiography.
• HEART score is a bedside risk calculator that combines history, ECG findings, age, risk factors, and troponin. It is a decision-support tool, not a diagnostic test on its own.
• D-dimer and BNP/NT-proBNP are separate blood tests aimed at different diagnoses (blood clot and heart failure, respectively), not markers of a heart attack.

Why a systematic workup exists at all

Chest pain sits at an awkward intersection: a large share of people who present with it have a benign, non-cardiac cause, but a small minority have a condition, acute myocardial infarction, pulmonary embolism, aortic dissection, or tension pneumothorax, where minutes matter. A structured pathway using an ECG, serial troponin, and a validated risk score exists to separate these groups without either missing dangerous disease or admitting everyone "just in case."

The 2021 AHA/ACC multisociety chest pain guideline describes an approach that integrates clinical history, physical exam, a 12-lead ECG, and troponin measurement to guide further testing and disposition. That guideline is the current reference point for chest pain triage in U.S. emergency and outpatient settings, and it replaced a patchwork of older, less unified recommendations.

The first minutes: ECG and physical exam

Current guidance calls for a 12-lead ECG within about 10 minutes of a patient presenting with chest pain. ST-segment elevation on that ECG is treated as an emergency: it typically triggers immediate activation of the cardiac catheterization lab, compressing a diagnostic process that might otherwise take hours into minutes.

Without ST-elevation, the ECG still contributes information. ST depression, T-wave inversion, or a new left bundle branch block raise suspicion for ACS and prompt serial troponin testing. A normal ECG lowers the probability of a heart attack but does not eliminate it; some non-ST-elevation events present with a normal or near-normal initial tracing, which is one reason troponin is drawn alongside the ECG rather than instead of it.

The physical exam adds context that no lab test provides directly: reproducible chest wall tenderness suggests a musculoskeletal cause, a substantial blood pressure difference between arms raises concern for aortic dissection, and a pericardial friction rub points toward pericarditis. None of these findings replace laboratory testing, but they shape which tests get prioritized and how urgently.

High-sensitivity troponin: the anchor test

High-sensitivity troponin assays have replaced older, conventional troponin tests in most U.S. and European hospitals. They detect much smaller concentrations of troponin, the protein released when heart muscle is damaged, which allows earlier detection after symptom onset than older assays, which often needed six to twelve hours to become positive.

Rapid rule-out protocols used in some hospitals draw troponin at presentation and again at a short, assay-specific interval (commonly one to three hours later). If both values fall below the assay's threshold and the change between them is minimal, myocardial infarction becomes very unlikely, though the exact sensitivity figures depend on the specific assay, the interval used, and the population studied, and should be verified against the primary validation literature for the assay in use at a given hospital rather than treated as a single universal number.

A single elevated troponin is not the same as a heart attack. Troponin can rise in heart failure, myocarditis, sepsis, kidney failure, and even after strenuous exercise. What distinguishes a Type 1 myocardial infarction is a rising or falling pattern on serial testing combined with a clinical picture consistent with reduced blood flow to the heart. A patient with chronic kidney disease, for example, may have a chronically elevated but stable troponin that reflects long-standing cardiac injury rather than an acute event, and that pattern needs to be interpreted against the person's baseline whenever it is available.

The HEART score: turning data into a decision

Raw lab values alone do not decide whether someone is admitted or sent home. Risk-stratification tools convert history, ECG findings, and lab results into a score that standardizes an otherwise subjective judgment. The HEART score is the most widely used version of this idea in emergency departments.

It has five components, each scored 0 to 2:

• History: how typical the chest pain is for ACS
• ECG: normal, non-specific changes, or significant ST changes
• Age: higher points for older patients
• Risk factors: hypertension, diabetes, smoking, obesity, known atherosclerotic disease, family history
• Troponin: normal, mildly elevated, or clearly elevated

Total scores range from 0 to 10. Lower scores (commonly grouped as 0 to 3) are associated with a low short-term risk of major adverse cardiac events and are often used to support same-day discharge with outpatient follow-up when combined with reassuring serial troponin results and a non-ischemic ECG. Higher scores prompt observation or admission for further testing. Exact event rates by score band vary across the validation studies and should not be quoted as a fixed number without checking the specific study population; the score is a decision aid, not a guarantee.

The HEART score does not replace clinical judgment, and it was derived and validated primarily in adults presenting to emergency departments with chest pain, not in every population that might use it. A low score in someone with an atypical presentation, a strong family history not fully captured by the risk-factor item, or a presentation pattern more common in women (who are more likely to have atypical symptoms such as fatigue, nausea, or back pain without classic chest pressure) still warrants clinical judgment rather than automatic reassurance.

A practical decision framework for matching symptoms to the right care setting

The facts above only matter if they change what someone actually does. The table below is a simplified decision aid built from the evidence discussed on this page. It is not a substitute for emergency evaluation and does not replace a clinician's judgment about an individual person.

Exceptions that should override a "low risk" reading of this table: a personal or strong family history of premature coronary disease, recent cocaine or stimulant use, pregnancy or postpartum status (which changes the differential to include conditions like spontaneous coronary artery dissection), and atypical presentations in women or older adults, where fatigue, nausea, or back or jaw discomfort may be the dominant symptom rather than classic chest pressure. In any of these situations, a lower threshold for emergency evaluation is reasonable even if the pain pattern looks reassuring on paper.

Other labs in the chest pain workup

Complete blood count (CBC). Anemia can cause or worsen chest discomfort by limiting oxygen delivery to the heart. An elevated white blood cell count may point toward infection or inflammation when pericarditis or pneumonia is being considered.

Basic metabolic panel (BMP). Electrolyte abnormalities, particularly potassium and magnesium, can trigger arrhythmias that present as chest discomfort. Creatinine and BUN help put a troponin result in context, since reduced kidney function is a well-recognized cause of chronically elevated troponin unrelated to ACS.

D-dimer. When pulmonary embolism is a concern, D-dimer is used as a screening test in patients judged to have a low or moderate pretest probability (commonly using a structured tool like the Wells score). A negative result in that low-probability group is used to help exclude PE without further imaging; a positive result is nonspecific and generally requires CT pulmonary angiography for confirmation. D-dimer is not useful as a stand-alone rule-out test in patients judged high-risk on clinical grounds.

BNP or NT-proBNP. These peptides are released by a stretched or strained ventricle. Elevated levels support heart failure as a contributor to chest tightness or breathlessness, and can help distinguish a cardiac from a pulmonary cause of shortness of breath accompanying chest discomfort. Reference thresholds vary by assay and by age, and should be interpreted using the specific lab's reported cutoffs rather than a single memorized number.

Lipid panel and hemoglobin A1c. These are not part of the acute rule-out process but are commonly drawn during a chest pain visit to assess longer-term cardiovascular risk and to inform decisions about statin therapy and diabetes management regardless of the acute diagnosis.

Imaging: when labs are not enough

Chest X-ray is usually the first imaging study. It cannot diagnose coronary artery disease, but it can identify pneumothorax, pleural effusion, a widened mediastinum suggestive of aortic dissection, or pneumonia, quickly and at low cost.

Coronary CT angiography (CCTA) has become a preferred non-invasive option for intermediate-risk chest pain patients without known coronary disease. The 2021 AHA/ACC guideline supports its use in this group, and it can provide a definitive anatomic answer (presence or absence of obstructive plaque) rather than only an indirect functional result. A normal CCTA has a high negative predictive value for obstructive coronary disease, though the precise figure depends on the study population and should not be treated as a fixed universal number.

Stress testing (exercise or pharmacologic, with nuclear imaging or echocardiography) remains useful when CCTA is not available or when the clinical question is about functional capacity rather than anatomy: can the person exercise to an adequate workload without symptoms or ECG changes.

Echocardiography is ordered when heart failure, valve disease, pericardial effusion, or a wall motion abnormality is suspected. It does not directly visualize the coronary arteries but shows the downstream effects of reduced blood flow.

Non-cardiac causes: often the majority of visits

A substantial share of chest pain evaluations end with a non-cardiac diagnosis. Recognizing these patterns helps avoid unnecessary catheterizations and prolonged anxiety, while still respecting that cardiac causes need to be excluded first when there is genuine uncertainty.

Gastroesophageal reflux disease (GERD) is a common non-cardiac cause. Burning substernal discomfort that worsens after meals or lying flat and improves with antacids points toward GERD; a trial of proton pump inhibitor therapy can be both diagnostic and therapeutic, with endoscopy reserved for persistent symptoms.

Musculoskeletal pain, often from costochondritis (inflammation at the costochondral junctions), is sharp, worsens with movement or palpation, and localizes to a specific spot on the chest wall. Treatment is typically NSAIDs and reassurance after cardiac causes have been reasonably excluded.

Anxiety and panic disorder can produce chest tightness, palpitations, shortness of breath, and a sense of impending doom that closely mimics a cardiac event. This is a diagnosis of exclusion: it should be considered only after appropriate cardiac evaluation, then supported with validated screening tools and treatment such as cognitive behavioral therapy or medication as appropriate.

Pulmonary causes, including pneumonia, pleuritis, and asthma exacerbation, usually come with cough, fever, or wheezing alongside the chest discomfort, and are evaluated with chest X-ray and pulse oximetry.

When to go to the emergency department

Certain features warrant immediate evaluation rather than a wait-and-see approach: sudden-onset pain radiating to the jaw, neck, or left arm; shortness of breath at rest; cold sweats; fainting or near-fainting; or new palpitations with signs of hemodynamic instability. The American Heart Association advises calling emergency services rather than driving yourself for chest pain that is new, unexplained, or lasts more than a few minutes (American Heart Association, Warning Signs of a Heart Attack, accessed 2026). Emergency medical services can obtain a field ECG and transmit it ahead of arrival, which can activate the cath lab before the patient reaches the hospital if ST-elevation is present.

Pain that has been stable for weeks, worsens only with specific movements, and is reproducible on palpation is less likely to be cardiac, and a same-day or next-day outpatient evaluation is often reasonable when risk factors are low and symptoms are not accelerating. That said, a first-ever episode of chest pain, or any change in a previously stable pattern, deserves a lower threshold for evaluation.

Outpatient follow-up and longer-term next steps

Ruling out an acute event in the emergency department is not the end of the process. Follow-up with a primary care provider or cardiologist within a few days is standard practice for people discharged with chest pain of uncertain cause, and outpatient stress testing or CCTA may follow if it was not done during the initial visit.

Risk-factor management typically starts immediately: statin therapy for elevated LDL, blood pressure control, smoking cessation counseling, and diabetes management all reduce future cardiovascular risk. Guideline-based primary prevention recommendations call for a formal 10-year atherosclerotic cardiovascular disease risk calculation in adults roughly age 40 to 75 to guide decisions about statin initiation; the specifics of that calculation and threshold should come from a clinician using current guideline tools rather than a generic online estimate.

For non-cardiac chest pain, treating the underlying cause, a PPI trial for suspected GERD, physical therapy for musculoskeletal pain, or SSRI therapy and CBT for panic disorder, is the relevant next step. Receiving a specific explanation of what was ruled out and what was found, rather than a vague "chest pain, unspecified" label, is widely regarded in emergency medicine literature as improving a patient's ability to know what to do if symptoms recur, though the exact effect on return-visit rates varies by study and should be checked against the primary literature before being cited as a fixed percentage.

What is established, what is plausible, and what is not established

Established: an ECG and troponin form the backbone of acute chest pain evaluation; high-sensitivity troponin detects myocardial injury earlier than older assays; the HEART score is a validated aid for identifying lower-risk patients; a substantial share of chest pain presentations are non-cardiac.

Plausible but not fully settled at the level of a single universal number: the exact sensitivity and miss rate of any specific rapid rule-out protocol, the precise negative predictive value of CCTA in a given population, and the exact reduction in return ED visits from clearer discharge diagnoses. These directions are well supported, but the specific figures depend on the study population, the assay, and the protocol, and should be verified against current primary literature or a treating clinician's institutional protocol rather than treated as fixed constants.

Not established as a general rule: that any single symptom pattern, including reproducible chest wall tenderness or reflux-like burning, is sufficient on its own to exclude a cardiac cause without any objective testing, particularly in people with cardiovascular risk factors, atypical presentations, or a first-ever episode.

A note on the evidence behind this page

This article synthesizes current multisociety chest pain guidance (AHA/ACC and partner societies) alongside established clinical understanding of troponin testing, risk stratification tools, and frequent non-cardiac etiologies of chest pain. Certain quantitative data from preceding versions (ED presentation frequencies, diagnostic miss rates with particular exclusion strategies, and reattendance reduction outcomes) lacked verification to a primary source in this update and were either converted to qualitative directional language or marked for primary literature confirmation. Any numerical statement requires validation by a qualified reviewer prior to standalone presentation.